bioMérieux: CE marking of a new Covid test
(CercleFinance.com) - bioMérieux has announced the CE marking of VIDAS SARS-COV-2 IgG II, a new generation IgG serological test, enabling the semi-quantitative detection of antibodies present in people who have been exposed to the coronavirus that causes the Covid-19 disease.
The French specialist of in-vitro diagnostics specifies that during an internal evaluation of the Pfizer-BioNTech and Moderna vaccines, this new VIDAS test has demonstrated its ability to detect anti-SARS-CoV-IgG antibodies after vaccination.
Hospitals and private laboratories can perform this new test on VIDAS analysers (MINI VIDAS, VIDAS and VIDAS 3) from bioMérieux, which are widely available, with 30,000 systems installed worldwide.
Copyright (c) 2021 CercleFinance.com. All rights reserved.